title: Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea.
abstract: Clearly new breast cancer models are necessary in developing novel therapies. To address this challenge, we examined mammary tumor formation in the Syrian hamster using the chemical carcinogen N-methyl-N-nitrosourea (MNU). A single 50mg/kg intraperitoneal dose of MNU resulted in a 60% incidence of premalignant mammary lesions, and a 20% incidence of mammary adenocarcinomas. Two cell lines, HMAM4A and HMAM4B, were derived from one of the primary mammary tumors induced by MNU. The morphology of the primary tumor was similar to a high-grade poorly differentiated adenocarcinoma in human breast cancer. The primary tumor stained positively for both HER-2/neu and pancytokeratin, and negatively for both cytokeratin 5/6 and p63. When the HMAM4B cell line was implanted subcutaneously into syngeneic female hamsters, tumors grew at a take rate of 50%. A tumor derived from HMAM4B cells implanted into a syngeneic hamster was further propagated in vitro as a stable cell line HMAM5. The HMAM5 cells grew in female syngeneic hamsters with a 70% take rate of tumor formation. These cells proliferate in vitro, form colonies in soft agar, and are aneuploid with a modal chromosomal number of 74 (the normal chromosome number for Syrian hamster is 44). To determine responsiveness to the estrogen receptor (ER), a cell proliferation assay was examined using increasing concentrations of tamoxifen. Both HMAM5 and human MCF-7 (ER positive) cells showed a similar decrease at 24h. However, MDA-MB-231 (ER negative) cells were relatively insensitive to any decrease in proliferation from tamoxifen treatment. These results suggest that the HMAM5 cell line was likely derived from a luminal B subtype of mammary tumor. These results also represent characterization of the first mammary tumor cell line available from the Syrian hamster. The HMAM5 cell line is likely to be useful as an immunocompetent model for human breast cancer in developing novel therapies.
authors: Department of Pharmacology, Toxicology, and Neuroscience, LSU Health Sciences Center, Shreveport, LA 71130, USA.
authors: Malari A
authors: MA
authors: Coburn
authors: Sabrina
authors: S
authors: Brueggemann
authors: Shilpa
authors: S
authors: Bhatia
authors: Bing
authors: B
authors: Cheng
authors: Benjamin D L
authors: BD
authors: Li
authors: Xiao-Lin
authors: XL
authors: Li
authors: Natalia
authors: N
authors: Luraguiz
authors: Yulia Y
authors: YY
authors: Maxuitenko
authors: Elysse A
authors: EA
authors: Orchard
authors: Songlin
authors: S
authors: Zhang
authors: Mariam A
authors: MA
authors: Stoff-Khalili
authors: J Michael
authors: JM
authors: Mathis
authors: Heather E
authors: HE
authors: Kleiner-Hancock
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced / Q000473:pathology*; D000818:Animals; D002273:Carcinogens; D045744:Cell Line, Tumor; D006224:Cricetinae; D004195:Disease Models, Animal; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology*; D008647:Mesocricetus; D008770:Methylnitrosourea
chemical_list: D002273:Carcinogens; D008770:Methylnitrosourea